Home Companies Catalysts Deep Dives
Wegovy semaglutide APPROVED
Drug Profile
ModalityPeptide
RouteSC
Therapy AreaCVRM
Launch2021-06-04
Peak Sales Est$25000M
Formulations[{"id":"wegovy-sc","doses":"0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg","route":"SC","device":"FlexTouch pen",
Companies
NVO (ORIGINATOR)100%
Mechanism: GLP-1 receptor agonist
Expert: Glucagon-like peptide-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite via hypothalamic signaling.
Everyday: Mimics a gut hormone that reduces appetite and helps control blood sugar by signaling fullness to the brain.
Targets: ["GLP-1R"]
Revenue History
PeriodRevenue ($M)
2025$11,200M
Q4 2025$3,100M
Programs (2)
IndicationStageKey StudyRegional Status
ObesityAPPROVEDSTEP 1-5[{"stage":"APPROVED","region":"US","approval_date":"2021-06-04"},{"stage":"APPRO
MASHAPPROVEDESSENCE[{"stage":"APPROVED","region":"US","approval_date":"2025-09-01"}]
Data from Supabase · Updated 2026-03-24